(firstQuint)RX-5902 Treatment of Subjects With Triple Negative Breast Cancer.

 In this dose-finding, open-label, single-agent study of RX-5902, subjects will be treated for up to 6 cycles of therapy.

 RX-5902 will be administered orally daily for 3 weeks followed by 1 week of rest in each cycle.

 All subjects will be followed for at least 30 days after the last dose of study agent for safety.

.

 RX-5902 Treatment of Subjects With Triple Negative Breast Cancer@highlight

The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.

